恒生指数早盘跌0.89% 恒生生物科技指数反弹2.16%

Group 1 - The Hang Seng Index fell by 0.89%, down 232 points, closing at 26,050 points, while the Hang Seng Tech Index dropped by 1.91% [1] - The early trading volume in Hong Kong stocks reached 142.3 billion HKD [1] - The Hang Seng Biotechnology Index rebounded by 2.16%, with notable gains in stocks such as InnoCare Pharma (up 10.88%) and 3SBio (up over 10%) [1] Group 2 - Fosen Pharmaceuticals surged nearly 74% during the session, with an early gain of 59.42% after the approval of Enzalutamide soft capsules and the potential selection of Metformin and Dapagliflozin for national procurement [1] - Rongchang Bio reported a 40% year-on-year increase in revenue for the first three quarters, with a significant reduction in losses, leading to a stock increase of 6.75% [2] - Spring Medical turned a profit in the third quarter, earning 77.06 million CNY, and saw its stock rise by over 21% as it actively expanded its international market [3] Group 3 - Newly listed stock Dipo Technology continued to rise, increasing by 18.97%, with its stock price doubling within three days of listing [4] - Ansteel Group's stock fell over 8%, with a net loss of 2.04 billion CNY for the first three quarters, although losses narrowed year-on-year [5] - Zoomlion Heavy Industry's stock rose over 3% after reporting a 24.89% year-on-year increase in net profit attributable to shareholders for the first three quarters, driven by its ongoing expansion in the mining machinery sector [5] Group 4 - China Everbright Bank's stock dropped by 5% following a decline in both revenue and profit for the first three quarters, facing pressure from fair value changes [5] - Huahao Zhongtian Pharmaceutical saw its stock drop over 37% due to a significant unlock of shares after one year of listing [6] - Lion King Holdings plummeted over 24% to a new low as it proposed to issue convertible bonds to raise approximately 260 million HKD for investments in gold and related products [7] - Air China experienced a drop of over 8%, with a more than 11% decline in net profit for the third quarter, and plans to raise no more than 20 billion CNY through A-share placement [8]